Why Do We Guess At Chemo When We Can Test with Dr Robert Hoffman

Send us Fan Mail

What if the next meaningful step in cancer care is not another buzzword, but a simple shift toward better testing and smarter nutrient control? Joe Grumbine sits down with Dr. Robert Hoffman for a candid, science-first conversation about keeping cancer in check by targeting what tumors need to grow, and why patients often have to push the system to get the most rational options.

We start with cancer metabolism and methionine dependence, including the low methionine diet and the methioninase enzyme approach. Then we dig into a mind-bending possibility: using the gut microbiome like a factory by inoculating it with bacteria that produce methioninase. Dr. Hoffman explains the research using E. coli strains that can generate active methioninase in the digestive tract, what “tumor targeting bacteria” means, and why defanged Salmonella and oral delivery raise big questions about safety, regulation, and real-world feasibility.

From there, we tackle personalized cancer treatment the way hospitals already handle infections: culture and sensitivity testing. Dr. Hoffman walks through decades of chemosensitivity testing history and the practical promise of 3D tumor culture methods like the histoculture drug response assay (HDRA). We also confront the uncomfortable reasons these tools are not widespread, including guidelines, incentives, workflow friction, and how tumor boards can devolve into guessing when time is short.

If you care about precision oncology that actually earns the word “precision,” this one is for you. Subscribe, share this with someone who needs more options, and leave a review so more patients can find the conversation. What part of this would you want your cancer center to offer first?

Intro for podcast

information about subscriptions

Support the show

Here is the link for Sunday's 4 pm Pacific time Zoom meeting